Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of $150,000,000, before deducting underwriting discounts and expenses payable by Catalyst. Catalyst has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts. The offering is expected to close on or about January 9, 2024, subject to customary closing conditions. All of the shares in the offering are being sold by Catalyst.

BofA Securities, Citigroup, Piper Sandler & Co., Cantor, and Truist Securities are acting as bookrunners for the offering. H.C. Wainwright & Co. and Oppenheimer & Co. are acting as co-lead managers for the offering.

Catalyst plans to use the net proceeds from the offering: (i) to fund the potential acquisition of new product candidates, and (ii) for general corporate purposes.

This offering is being made pursuant to an automatic shelf registration statement (including a prospectus) filed by Catalyst with the Securities and Exchange Commission (“SEC”) on September 8, 2023. The offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and a final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available at the SEC’s website at https://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at [e-mail]; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at [phone].